Drug intelligence / Profile preview

antiviral inhalation solution (TCM)

Development stage: Preclinical
Lead developer: Beijing Yingkerei Pharmaceutical Technology
Administration: Inhalation

Overview

Antiviral Inhalation Solution (TCM) is a traditional Chinese medicine (TCM) candidate developed by Beijing Yingkerei Pharmaceutical Technology for the treatment of viral respiratory infections. The drug is formulated specifically for administration via nebulization, a delivery route designed to achieve high local concentrations of active herbal constituents directly in the respiratory tract while potentially reducing systemic exposure and side effects. As part of Yingkerei's specialized platform for inhaled TCMs, this solution is intended to provide rapid therapeutic effects against respiratory viruses. It is currently in the preclinical stage of development.

Other names: 吸入用抗病毒溶液Antiviral Inhalation Solution

Beyond the preview

Go deeper on antiviral inhalation solution (TCM).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on antiviral inhalation solution (TCM).

Explore the full profile